platinum has been researched along with Carcinoma, Medullary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albiges, L; Allory, Y; Auclin, E; Barthelemy, P; Brihoum, M; Chevreau, C; Coquan, E; de Reyniès, A; Elaidi, RT; Fléchon, A; Gravis, G; Gross-Goupil, M; Joly, C; Laguerre, B; Oudard, S; Pécuchet, N; Rolland, F; Thibault, C; Timsit, MO | 1 |
| Carlo, MI; Chaim, J; Chen, YB; Coskey, D; Feldman, DR; Hakimi, AA; Hsieh, JJ; Kemel, Y; Lee, CH; Motzer, RJ; Nanjangud, GJ; Patil, S; Schram, AM; Voss, MH; Woo, K | 1 |
1 trial(s) available for platinum and Carcinoma, Medullary
| Article | Year |
|---|---|
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Medullary; Carcinoma, Renal Cell; Gemcitabine; Humans; Hypertension; Kidney; Kidney Neoplasms; Platinum; Prospective Studies; Retrospective Studies | 2023 |
1 other study(ies) available for platinum and Carcinoma, Medullary
| Article | Year |
|---|---|
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Topics: Adolescent; Adult; Aged; Carcinoma, Medullary; Child; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kidney Neoplasms; Male; Middle Aged; Pharmacogenomic Variants; Platinum; Retrospective Studies; Sequence Analysis, DNA; SMARCB1 Protein; Survival Analysis; Translocation, Genetic; Treatment Outcome; Young Adult | 2017 |